Increase of hepcidin plasma and urine levels is associated with acute proctitis and changes in hemoglobin levels in primary radiotherapy for prostate cancer

Journal of Cancer Research and Clinical Oncology

Volumn 133, Issue 5, 2007, Pages 297-304

  Christiansen, Hans ^a   Saile, Bernhard ^a   Hermann, Robert M ^a   Rave Fränk, Margret ^a   Hille, Andrea ^a   Schmidberger, Heinz ^a,b   Hess, Clemens F ^a   Ramadori, Giuliano ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Cytokines; Hepcidin; Proctitis; Prostate cancer; Radiotherapy

Indexed keywords

FERRITIN; HEPCIDIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; TRANSFERRIN; TUMOR NECROSIS FACTOR ALPHA;

AGED; ARTICLE; BLOOD CELL COUNT; BLOOD SAMPLING; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG URINE LEVEL; FERRITIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; MALE; PRIORITY JOURNAL; PROCTITIS; PROSTATE CANCER; RADIATION INJURY; TOXICITY TESTING; TRANSFERRIN BLOOD LEVEL; URINALYSIS; WILCOXON SIGNED RANKS TEST;

ACUTE DISEASE; ADENOCARCINOMA; AGED; ANTIMICROBIAL CATIONIC PEPTIDES; HEMOGLOBINS; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; PROCTITIS; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34248160532     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-006-0170-0     Document Type: Article

References (38)

1. Andrews NC (1999) Disorders of iron metabolism. N Engl J Med 341:1986-1995
2. Arpin D, Perol D, Blay JY, Falchero L, Claude L, Vuillermoz-Blas S, Martel-Lafay I, Ginestet C, Alberti L, Nosov D, Etienne-Mastroianni B, Cottin V, Perol M, Guerin JC, Cordier JF, Carrie C (2005) Early variations of circulating interleukin-6 and interleukin-10 levels during thoracic radiotherapy are predictive for radiation pneumonitis. J Clin Oncol 23:8748-8756
3. Boustany R, Zerbib M (2005) Anaemia and prostatic cancer. Prog Urol 15:604-610
4. Christiansen H, Sheikh N, Saile B, Reuter F, Rave-Frank M, Hermann RM, Dudas J, Hille A, Hess CF, Ramadori G (2006) X-radiation leads to up-regulation of hepcidin and down-regulation of hemojuvelin and ferroportin-1 gene expression in rat liver. Radiology (in press)
5. Corradini E, Ferrara F, Pietrangelo A (2004) Iron and the liver. Pediatr Endocrinol Rev 2:245-248
6. Ganz T (2003) Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 102:783-788
7. Ganz T (2004) Hepcidin in iron metabolism. Curr Opin Hematol 11:251-254
8. Ganz T, Nemeth E (2006) Iron imports. IV. Hepcidin and regulation of body iron metabolism. Am J Physiol Gastrointest Liver Physiol 290:G199-G203
9. Harrison LB, Shasha D, Homel P (2002) Prevalence of anemia in cancer patients undergoing radiotherapy: prognostic significance and treatment. Oncology 63:11-18
10. Herskind C, Bamberg M, Rodemann HP (1998) The role of cytokines in the development of normal-tissue reactions after radiotherapy. Strahlenther Onkol 174:12-15
11. Indaram AV, Visvalingam V, Locke M, Bank S (2000) Mucosal cytokine production in radiation-induced proctosigmoiditis compared with inflammatory bowel disease. Am J Gastroenterol 95:1221-1225
12. International Commission on Radiation Units and Measurements (1993) Prescribing, recording and reporting photon beam therapy. ICRU Report No. 50, MP, Bethesda
13. Jurado RL (1997) Iron, infections, and anemia of inflammation. Clin Infect Dis 25:888-895
14. Koc M, Taysi S, Sezen O, Bakan N (2003) Levels of some acute-phase proteins in the serum of patients with cancer during radiotherapy. Biol Pharm Bull 26:1494-1497
15. Koper PC, Stroom JC, van Putten WL, Korevaar GA, Heijmen BJ, Wijnmaalen A, Jansen PP, Hanssens PE, Griep C, Krol AD, Samson MJ, Levendag PC (1997) Acute morbidity reduction using 3DCRT for prostate carcinoma (a randomized study). Int J Radiat Oncol Biol Phys 43:727-734
16. Kovacs CJ, Daly BM, Evans MJ, Johnke RM, Lee TK, Karlsson UL, Allison R, Eaves GS, Biggs LM (2003) Cytokine profiles in patients receiving wide-field + prostate boost radiotherapy (xRT) for adenocarcinoma of the prostate. Cytokine 23:151-163
17. Krause A, Neitz S, Magert HJ, Schulz A, Forssmann WG, Schulz-Knappe P, Adermann K (2000) LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett 480:147-150
18. Lee P, Peng H, Gelbart T, Wang L, Beutler E (2005) Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proc Natl Acad Sci USA 102:1906-1910
19. Lipinski P, Starzynski R (2004) Regulation of body iron homeostasis by hepcidin. Postepy Hig Med Dosw 58:65-73
20. Lipman AJ, Lawrence DP (2004) The management of fatigue in cancer patients. Oncology (Williston Park) 18:1527-1535
21. McGrath H, Rigby PG (2000) Hepcidin: inflammation's iron curtain. Rheumatology 43:1323-1325
22. Means RT (1999) Advances in the anemia of chronic disease. Int J Hematol 70:7-12
23. Means RT (2004) Hepcidin and cytokines in anaemia. Hematology 9:357-362
24. Michalski JM, Purdy JA, Winter K, Roach M 3rd, Vijayakumar S, Sandler HM, Markoe AM, Ritter MA, Russell KJ, Sailer S, Harms WB, Perez CA, Wilder RB, Hanks GE, Cox JD (2000) Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys 46:391-402
25. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T (2003) Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 101:2461-2463
26. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T (2004) IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 113:1271-1276
27. Ozsahin M, Azria D, Beer K, Mirimanoff RO, Zouhair A (2005) External radiotherapy and anaemia treatment: state of the art. Swiss Med Weekly 135:4-10
28. Park CH, Valore EV, Waring AJ, Ganz T (2001) Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 276:7806-7810
29. Petrini B, Andersson B, Strannegard O, Wasserman J, Blomgren H, Glas U (1992) Monocyte release and plasma levels of interleukin-6 in patients irradiated for cancer. In Vivo 6:531-534
30. Pietrangelo A (2005) Non-HFE hemochromatosis. Semin Liver Dis 25:450-460
31. Rube CE, Rodemann HP, Rube C (2004) The relevance of cytokines in the radiation-induced lung reaction. Experimental basis and clinical significance. Strahlenther Onkol 180:541-549
32. Sharma N, Butterworth J, Cooper BT, Tselepis C, Iqbal TH (2005) The emerging role of the liver in iron metabolism. Am J Gastroenterol 100:201-206
33. Sheikh N, Batusic D, Dudas J, Tron K, Neubauer K, Saile B, Ramadori G (2006) Hepcidin and hemojuvelin gene-expression in rat liver damage: in vivo and in vitro studies. Am J Physiol Gastrointest Liver Physiol 291:G482-490
34. Sobin LH, Wittekind C (1997) TNM classification of malignant tumours, 5th edn. Wiley/Liss, New York
35. Storey MR, Pollack A, Zagars G, Smith L, Antolak J, Rosen I (2000) Complications from radiotherapy dose escalation in prostate cancer (preliminary results of a randomized trial). Int J Radiat Oncol Biol Phys 48:635-642
36. Theodorsson E (2006) Haemochromatosis, hepcidin and disorders of iron metabolism: fields of substantial clinical relevance and current advances. Scand J Clin Lab Invest 66:79-82
37. Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, Gunderson L, McCormick B, Morrisintegral M, Rich T, Shipley W, Curran W (2000) Common toxicity criteria: version 2.0 an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 47:13-47
38. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176-181